Photo via Al Jazeera

Dozens of people sue GLP-1 drug companies over alleged vision loss

Read the original at Al Jazeera ↗
Cite

Al Jazeera Staff. (2026, September 22). Dozens of people sue GLP-1 drug companies over alleged vision loss. Al Jazeera. https://www.aljazeera.com/news/2026/9/22/dozens-sue-glp-1-drug-companies-over-vision-loss-allegations?traffic_source=rss

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Al Jazeera · collected 2026-09-22 · by Al Jazeera Staff

Quick Summary

People across the United States have filed lawsuits against companies that produce GLP-1 weight-loss drugs, such as Ozempic and Mounjaro, claiming these medications caused a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The plaintiffs allege that the drugs significantly increase their risk of developing NAION, with some cases reported just months after starting treatment. Novo Nordisk, maker of popular GLP-1 drugs, disputes these claims and states its studies show no increased risk associated with their products.
Written by AI on 2026-09-22, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Dozens of people in the United States have filed lawsuits against GLP-1 drug companies like Novo Nordisk (makers of Ozempic and Wegovy) and Eli Lilly (makers of Mounjaro and Zepbound), claiming that their weight-loss drugs caused a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The lawsuits, supported by claims from hundreds of consumers, assert that these popular medications may increase the risk of NAION. Although Novo Nordisk has stated that its products are safe and lacks merit in the accusations, they face a significant challenge given analysts’ projections that this industry could generate about $100 billion annually over the next decade due to widespread use among millions of Americans combating obesity. The American Academy of Ophthalmology and North American Neuro-Ophthalmology Society note that while there are reports suggesting an increased risk, studies also indicate no correlation with NAION, emphasizing that the overall magnitude of this risk remains low.

Written for “GLP-1 Drug Lawsuits Vision Loss” on 2026-11-18, grounded in this article and the 1 other(s) covering the same event.

How they differ

2 outlets covered “GLP-1 Drug Lawsuits Vision Loss”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Al JazeeraThis outlet22 Sep

People across the United States have filed lawsuits against companies that produce GLP-1 weight-loss drugs, such as Ozempic and Mounjaro, claiming these medications caused a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The plaintiffs allege that the drugs significantly increase their risk of developing NAION, with some cases reported just…

Dozens of people sue GLP-1 drug companies over alleged vision loss (this article)
Fox News22 Sep

Hundreds of consumers are suing Novo Nordisk and Eli Lilly over their weight-loss drugs, alleging that medications like Ozempic, Wegovy, Mounjaro, and Zepbound may increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss. According to recent studies in JAMA Ophthalmology, patients using semaglutide experienced approximately four times higher relative…

Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss →

Compared with similar articles

This article reads unscored and hedges 17% of its claims. Each row says how that neighbour differs.
South China Morning Post
Leans left Hedges 0 of 1 claims Outlet record 62/100
“The articles describe different aspects related to GLP-1 drugs but do not report on the same specific incident.”
Fox News
Hedges 10 of 33 claims Outlet record 67/100
The Sydney Morning Herald
Hedges 3 of 30 claims Outlet record 61/100
“The articles discuss different aspects of GLP-1 drugs but describe distinct events: one is about lawsuits filed over vision loss claims, and the other is McDonald's response to the popularity of Ozempic.”
Daily Mail
Hedges 7 of 45 claims Outlet record 70/100
“Article A describes a single lawsuit filed by Ed Gillen, while Article B mentions dozens of lawsuits being filed collectively.”

Story

GLP-1 Drug Lawsuits Vision Loss
Health · 2 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
23
sentences that state something as happening or true
Uncertain
17%
4 of 23 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
Al Jazeera's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
2
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-22 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Al Jazeera · 6027 article(s) · 4 correction(s) detected
Running correction rate · 4 correction(s)

Who wrote this

Al Jazeera Staff
1157 article(s) here · 1 carrying a prediction
His death has long been the subject of conspiracy theories, with some claiming he was killed over fears he would provide damning evidence linking prominent public figures to cases of sexual abuse, rape and paedophilia.
He added that China sought to “provide a more stable, predictable and beneficial environment for global enterprises” and would continue to expand access in its manufacturing and services sectors.
“While sanctions, tariffs and export restrictions may still exert a certain deterrent effect, they are incapable of halting growth – let alone crushing the economies of competitors.”
Recommended Stories list of 3 items- list 1 of 3Siege fuels disease fears in Yemen’s Taiz - list 2 of 3Houthi advance on Aden may spur resurgence of Yemen’s southern separatists - list 3 of 3Yemeni parliament approves law designating Houthis as ‘terrorists’ And yet, speaking during a recent visit to Sanaa, Mohammed said the Houthis were able to continue getting supplies to their fighters.
“If there is no forest, there are no uncontacted peoples,” Teresa Mayo, a senior researcher at Survival International, told Al Jazeera in a report on the Nukak.
In its first annual report submitted on Tuesday, the board cautioned that, without immediate steps to implement the 2025 ceasefire deal, the truce between Israel and Hamas may be on the brink of collapse.
The order would potentially bring the government and its troops into direct confrontation with the armed group.
“These are extremely serious allegations, and our collective response should send a strong message that we will act swiftly and robustly where we suspect this kind of espionage activity taking place,” Taylor said.
- list 3 of 4Why China will not comply with US sanctions on Iran - list 4 of 4US
The prediction market platform Kalshi has ended wagers on whether United States President Donald Trump would use specific words on certain dates in his speeches.
2026-11-17 · mixed framing · Kalshi halts Trump speech bets after CFTC order
Wire or desk byline, not an individual reporter.
Also by Al Jazeera Staff
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 1157 articles by Al Jazeera Staff →

Topics

3WeightWatchers Mounjaro Novo Nordisk Ozempic the United States

Subjects

Novo Nordisk ORG · 5× 3WeightWatchers ORG · 1× District Court ORG · 1× Eli Lilly ORG · 1× New Jersey GPE · 1× Pennsylvania GPE · 1× The Wall Street Journal ORG · 1× The Washington Post ORG · 1× Weitz & Luxembourg ORG · 1× the United States GPE · 1×

Narrative

The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology said that despite the reports that there is a small possible increase in risk, there are also studies that report no correlation and “the overall magnitude of the risk of NAION remains low.”
framing: assertive · carried by 1 article(s) · first seen 2026-09-22
The cases and alleged risk could present a significant challenge to a fledgling industry that analysts expected to generate about $100bn in annual sales in the next 10 years after being taken by millions of people in the US and making inroads into combatting widespread obesity in the country.
2026-09-22 · Al Jazeera
Dozens of people sue GLP-1 drug companies over alleged vision loss · assertive framing

Claims (23 extracted, 4 hedged)

Dozens of people have filed lawsuits in the United States against GLP-1 companies, which make popular weight-loss drugs like Ozempic and Mounjaro, claiming their products caused a rare condition that can cause permanent vision loss, US media outlets report. asserted
outlets → file → loss
The cases and alleged risk could present a significant challenge to a fledgling industry that analysts expected to generate about $100bn in annual sales in the next 10 years after being taken by millions of people in the US and making inroads into combatting widespread obesity in the country. uncertain
analysts → allege → country
Recommended Stories list of 3 items- list 1 of 3WeightWatchers files for bankruptcy amid rise of weight-loss drugs - list 2 of 3Could asserted
3WeightWatchers → file → drugs
weight loss drugs fix UK’s unemployment problem? asserted
drugs → fix → problem
A spokesperson for Novo Nordisk, the pharmaceutical giant that makes Wegovy and Ozempic, said the lawsuits lacked merit and the company was vigorously contesting them, according to The Wall Street Journal, while Eli Lilly, which produces Zepbound, did not comment on the litigation but said it was reviewing the data on potential health risks. uncertain
it → make → risks
The lawsuits asserted that the drugs cause nonarteritic anterior ischemic optic neuropathy, or NAION, an eye condition that prevents adequate blood flow and damages the optic nerve, potentially resulting in permanent vision loss. asserted
that → assert → loss
In one lawsuit filed by a woman in Pennsylvania described to The Washington Post, the patient said that after taking medication for her diabetes, her vision was like looking through a “fishbowl”. asserted
vision → file → fishbowl
Two weeks later, she was diagnosed with NAION. asserted
she → diagnose → NAION
Scientists have been researching the possible connection between the condition and weight-loss drugs for years, but their findings remained mixed. asserted
findings → research → years
NAION is a condition in which sudden loss of vision happens due to a painless reduction of blood flow to the optic nerve. asserted
loss → happen → nerve
It is often also referred to as an “eye stroke”. asserted
It → refer → stroke
Scientific research has pointed to possible incidents in which patients who have taken GLP-1s end up being more likely to develop the condition. asserted
who → point → condition
It remains unclear how or if the drug is the cause of these problems. uncertain
drug → remain → problems
Researchers have said, however, that for those who do develop the condition, it happens within the first six to 18 months of starting a GLP-1 medication. asserted
it → say → medication
What lawsuits have been filed? asserted
lawsuits → file → ?
A personal-injury firm in the US called Weitz & Luxembourg has filed more than 90 lawsuits against Novo Nordisk in a New Jersey state court since 2025 on behalf of patients who have developed NAION while taking their products. asserted
who → call → products
Separate lawsuits have also been filed in the US District Court for the Eastern District of Pennsylvania, claiming that GLP-1 treatments caused NAION and drugmakers failed to adequately warn of their risks. asserted
drugmakers → file → risks
A Novo Nordisk company-funded study conducted randomised trials on GLP-1 patients and said they found the drugs do not cause any increase in the risk of NAION. asserted
drugs → fund → NAION
Dr Tina Vilsboll, a senior medical officer at Novo Nordisk and the lead author of the study, said she sees “no causality” and there are no “indications that we should really be worried about NAION”. asserted
we → say → NAION
The European Medicines Agency said the eye condition could impact one of every 10,000 GLP-1 users who have diabetes. uncertain
who → say → diabetes
The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology said that despite the reports that there is a small possible increase in risk, there are also studies that report no correlation and “the overall magnitude of the risk of NAION remains low.” asserted
magnitude → say → NAION
Despite the lawsuits, the US has not added any warnings on GLP-1 medications. asserted
US → add → medications
The US Food and Drug Administration has been investigating the link after early reports on the connection in 2024. asserted
Administration → investigate → 2024
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support